FindTrial
Sign In

Effects of a medication for improving outcome in brain aneurysm patients.

Effects of nimodipine on intra-arterial diameter and Global circulation times in patients of sub arachnoid hemorrhage - An observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/09/073486
Enrollment
20
Registered
2024-09-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G968- Other specified disorders of central nervous system Health Condition 2: G968- Other specified disorders of central nervous system

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Sher-i-kashmir institute of medical sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All cases diagnosed with sub arachnoid hemorrhage

Exclusion criteria

Exclusion criteria: Patients with previous history of hypersensitivity reaction to nimodipine Patients with liver failure Pregnant patients Patients in hypotension

Design outcomes

Primary

MeasureTime frame
To study the changes in intraarterial diameter during various stages of treatment in patients with Aneurysmal SAH with the administration of oral, intravenous and intraarterial nimodipine.Timepoint: day 0, day 1 post intervention, day 2 ,day 3—

Secondary

MeasureTime frame
To compare the changes in in intraarterial diameter during various stages of treatment in patients with Aneurysmal SAH with the administration of oral, intravenous & intraarterial nimodipine. To study the correlation with the changes in vascular diameter with GCS & GOS. Timepoint: 24 hours 48 hours 72 hours—

Countries

India

Contacts

Public ContactDr Jasima Javeed

Sher-i-kashmir institute of medical sciences

zulfiqaraliiii@yahoo.com8082999110

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026